DEBNsp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
DEBN develops a medical device for prostate biopsy, consisting of a biopsy needle and an anesthetic needle with a polymer coating that releases a drug directly into the prostate. The first model contains polyvinyl alcohol and amikacin; the device is intended to potentially reduce infections associated with transrectal biopsy.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2017-08-04. Active
08 2490 1057 0000 9901 9423 2870- 53 2490 0005 0000 4520 4375 7511
- 61 2490 1057 0000 9900 9423 2870
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
9 public aid cases recorded, with a total value of $1,204,643.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 11, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $8,512$8,512 | Towarzystwo Inwestycji Społeczno-Ekonomicznych S.A. | |
| May 15, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | PREZYDENT MIASTA GDAŃSK | |
| Jul 9, 2019 | Aid for research and development projects: experimental development | $456.4K$456,371 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-01-01 | Ocena kliniczna DEBN (Drug-Eluting Biopsy Needle) jako nowej metody profilaktyki antybakteryjnej u pacjentów poddawanych przezodbytniczej biopsji stercza. | $844.9K$844,915 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The company will be represented by two members of the management board jointly, with the proviso that, if a member of the management board is appointed by Alfabeat Alfa spółka z ograniczoną odpowiedzialnością spółka komandytowo-akcyjna, the submission of declarations of will on behalf of the company will always require the joint action of the Vice-President of the Management Board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Alfabeat Alfa Sp. z o.o. Spółka Komandytowo- Akcyjna | 50 | $675.31 | 4.8924% |
Cet Advisors Limited | 25 | $337.66 | 2.4462% |
Artur Mariusz Gibas (47) | 130 | $1,755.81 | 12.7202% |
Michał Łukasz Krużycki (46) | 90 | $1,215.56 | 8.8063% |
| 100 | $1,350.62 | 9.7847% | |
| 450 | $6,077.80 | 44.0313% | |
Marcin Jan Sieczkowski (42) | 130 | $1,755.81 | 12.7202% |
Others | 47 | $634.79 | 4.5987% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| Scope FluidicsS.A. | $1,264,188.85 | scopefluidics.com | ||
| UrtesteS.A. | $701,908.59 | urteste.com | ||
| MultiqureS.A. | $284,781.52 | purebiologics.com | ||
| Medestosp. z o.o. | $120,911.45 | medesto.com.pl | ||
| Exomedissp. z o.o. | $26,633.41 | exomedis.com | ||
| Air Abrasion Systemsp. z o.o. | $25,764.88 | airabrasion.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-21 | Share capital change (43,700.00 PLN → 45,100.00 PLN) | |
| 2024-05-28 | Share capital change (42,000.00 PLN → 43,700.00 PLN) | |
| 2024-03-11 | Share capital change (40,000.00 PLN → 42,000.00 PLN) | |
| 2023-12-29 | Share capital change (38,650.00 PLN → 40,000.00 PLN) | |
| 2023-12-11 | Share capital change (36,700.00 PLN → 38,650.00 PLN) |
FAQ
Last updated: 2026-04-24